Progression-Free Survival
In DESTINY-Breast03, a head-to-head study vs T-DM1,
ENHERTU delivered ground breaking progression-free survival in 2L to patients with HER2+ mBC1
Primary endpoint demonstrated superiority in progression-free survival as assessed by BICR
Primary endpoint demonstrated superiority in progression-free survival as assessed by BICR
aPresented as 6 decimal points.1
Similar mPFS results were observed in prespecified exploratory patient subgroups in the ENHERTU arm1
Prespecified exploratory analysis reinforced the mPFS benefit of ENHERTU over T-DM1 in a range of patients with HER2+ mBC1
Confirmed Objective Response Rate
In DESTINY-Breast03, a head-to-head study vs T-DM1,
~80% of patients achieved a response with ENHERTU1
Secondary endpoint: Confirmed objective response rate per BICR
Nearly all enrolled patients benefited from ENHERTU: only 1.1% of patients experienced disease progression (vs 17.5% with T-DM1)1
Tumour Response
In DESTINY-Breast03, ENHERTU delivered tumor responses to more patient’s vs T-DM11
Exploratory endpoint: Best percent change from baseline in the sum of diameters of measurable tumors
bResults in patients treated with ENHERTU 5.4 mg/kg Q3W and T-DM1 3.6 mg/kg Q3W, respectively, who had both baseline and postbaseline target lesions assessed by ICR (ENHERTU n=245/261; T-DM1 n=228/263).1
Overall Survival
In DESTINY-Breast03, ENHERTU delivered tumor responses to more patient’s vs T-DM11
Overall survival was evaluated in patients receiving ENHERTU or T-DM11
Secondary endpoint: Overall survival was immature at time of data cutoff (May 21, 2021)4
Median overall survival was not reached at time of data analysis2
2L, second line; BICR, blind independent central review; CI, confidence interval; CR, complete response; DCR, disease control rate; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; HR-, hormone receptor negative; HR+, hormone receptor positive; mBC, metastatic breast cancer; mPFS, median progression-free survival; NE, not evaluable; NR, not reached; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; T-DM1, ado-trastuzumab emtansine.
References:
1. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer: results of the randomized, phase 3 study DESTINY-Breast03. Presented at: European Society of Medical Oncology; September 16-21, 2021; Virtual.
2. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022; 386:1143-1154
